Hrt Financial LP Uni Qure N.V. Transaction History

Hrt Financial LP

$15.6 Billion
Q1 2024

A detailed history of Hrt Financial LP transactions in Uni Qure N.V. stock. As of the latest transaction made, Hrt Financial LP holds 45,035 shares of QURE stock, worth $180,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,035

Previous 56,881 20.83%

Holding current value

$180,590

Previous $385,000 39.22%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.82 - $6.93 $57,097 - $82,092	-11,846 Reduced 20.83%	45,035 $234,000
Q4 2023 Feb 09, 2024	SELL	$5.63 - $8.27 $871,326 - $1.28 Million	-154,765 Reduced 73.12%	56,881 $385,000
Q3 2023 Nov 13, 2023	BUY	$6.71 - $11.83 $1.42 Million - $2.5 Million	211,646 New	211,646 $1.42 Million
Q4 2022 Feb 10, 2023	BUY	$18.12 - $27.32 $2.3 Million - $3.47 Million	127,108 New	127,108 $2.88 Million
Q2 2022 Aug 12, 2022	BUY	$13.15 - $20.45 $1.18 Million - $1.83 Million	89,684 New	89,684 $1.67 Million

Q1 2022 May 16, 2022	SELL	$14.54 - $21.5 $278,513 - $411,832	-19,155 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $387,697 - $689,771	19,155 New	19,155 $397,000
Q3 2021 Nov 15, 2021	SELL	$26.01 - $38.22 $1.16 Million - $1.7 Million	-44,532 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$29.97 - $37.17 $1.33 Million - $1.66 Million	44,532 New	44,532 $1.37 Million
Q3 2020 Nov 13, 2020	SELL	$35.98 - $47.66 $380,632 - $504,195	-10,579 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $476,689 - $716,621	10,579 New	10,579 $476,000
Q1 2019 May 14, 2019	SELL	$27.39 - $68.41 $274,776 - $686,289	-10,032 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$22.8 - $33.93 $228,729 - $340,385	10,032 New	10,032 $289,000

Others Institutions Holding QURE

# of Institutions

148

Shares Held

34.1M

Call Options Held

1.07M

Put Options Held

603K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $187M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Account